SFM
ENGN icon

Sphera Funds Management’s enGene Therapeutics ENGN Stock Holding History

Sphera Funds Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-504,409
Closed -$3.45M – 111
2025
Q3 		$3.45M Hold
504,409
– – 0.73% 43
2025
Q2 		$1.84M Sell
504,409
-23,956
-5% -$89.9K 0.43% 73
2025
Q1 		$2.37M Sell
528,365
-31,635
-6% -$196K 0.55% 56
2024
Q4 		$3.72M Buy
+560,000
New +$4.35M 0.67% 55

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sphera Funds Management's ENGN Position: Q4 2025 in Review

Sphera Funds Management sold out of enGene Therapeutics (ENGN) in Q4 2025, closing a stake of 504,409 shares — an estimated $3.45M sold.

Sphera Funds Management first reported a position in ENGN in Q4 2024 and held it in 4 quarters. The position peaked at $3.72M in Q4 2024. 57 funds tracked by Wall St. Rank hold ENGN as of Q4 2025.

  • Sphera Funds Management reported no remaining enGene Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sphera Funds Management sold 504,409 enGene Therapeutics shares in Q4 2025, an estimated $3.45M.
  • Sphera Funds Management first reported a position in enGene Therapeutics in Q4 2024 and held it in 4 quarters.
  • Sphera Funds Management's enGene Therapeutics position peaked at $3.72M in Q4 2024.
  • 57 funds tracked by Wall St. Rank held enGene Therapeutics as of Q4 2025.

Based on Sphera Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.